117 related articles for article (PubMed ID: 30113582)
21. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC;
Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170
[TBL] [Abstract][Full Text] [Related]
22. Further Investigation of the Role of
Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
[No Abstract] [Full Text] [Related]
23. Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.
de Jong C; Sanders S; Creemers GJ; Burylo AM; Taks M; Schellens JHM; Deenen MJ
Br J Clin Pharmacol; 2017 Sep; 83(9):2120-2122. PubMed ID: 28560854
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
Bhavsar AP; Gunaretnam EP; Li Y; Hasbullah JS; Carleton BC; Ross CJ
PLoS One; 2017; 12(4):e0175711. PubMed ID: 28406961
[TBL] [Abstract][Full Text] [Related]
25. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
[TBL] [Abstract][Full Text] [Related]
26. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
27. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
JAMA Oncol; 2017 Nov; 3(11):1558-1562. PubMed ID: 28448657
[TBL] [Abstract][Full Text] [Related]
28. Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.
Olgun Y; Aktaş S; Altun Z; Kırkım G; Kızmazoğlu DÇ; Erçetin AP; Demir B; İnce D; Mutafoğlu K; Demirağ B; Ellidokuz H; Olgun N; Güneri EA
Int J Pediatr Otorhinolaryngol; 2016 Nov; 90():64-69. PubMed ID: 27729156
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
31. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
32. Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD; Jiménez-Méndez R; Rodríguez-Islas F; Fierro-Evans M; Vázquez-Gómez BE; Medina-Sansón A; Clark P; Carleton B; Ross C; Hildebrand C; Castañeda-Hernández G; Rivas-Ruiz R
Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1456-60. PubMed ID: 25037447
[TBL] [Abstract][Full Text] [Related]
33. [Ototoxicity of cisplatin].
Kitoh R; Usami S
Nihon Rinsho; 2015 Feb; 73 Suppl 2():480-5. PubMed ID: 25831807
[No Abstract] [Full Text] [Related]
34. Influence of Genetic Variation in
Agema BC; Koolen SLW; With M; Doorn NV; Heersche N; Hoop EO; Visser S; Aerts JGJV; Bins S; Schaik RHNV; Mathijssen RHJ
Genes (Basel); 2020 Mar; 11(4):. PubMed ID: 32230800
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
Lanvers-Kaminsky C; Ciarimboli G
Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
[TBL] [Abstract][Full Text] [Related]
36. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.
Weinshilboum RM
Cell Mol Neurobiol; 2006; 26(4-6):539-61. PubMed ID: 16807786
[TBL] [Abstract][Full Text] [Related]
38. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
39. Variants in
Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
[No Abstract] [Full Text] [Related]
40. Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update.
Scott EN; Joseph AA; Dhanda A; Tanoshima R; Brooks B; Rassekh SR; Ross CJD; Carleton BC; Loucks CM
Ther Drug Monit; 2023 Dec; 45(6):714-730. PubMed ID: 37726872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
